Lexicon Pharmaceuticals Inc. – New Analysis of SCORED Trial Demonstrates Sotagliflozin's Effect on Reducing Albuminuria in Patients with Type 2 Diabetes and Chronic Kidney Disease – Marketscreener.com
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a new post hoc analysis of results from the SCORED Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2…